Bulletin June

• A new four-week clinical trial has established that daily L-tyrosine supplementation is safe and well-tolerated for healthy adults. • Researchers monitored a comprehensive range of health markers, including liver and kidney function, blood sugar, cholesterol levels, and blood amino acid concentrations. • The study found no significant differences in clinical safety markers between the various L-tyrosine doses and the placebo group.

• A new study has revealed the neurological process by which the brain updates predictions and adapts to change, specifically regarding how it distinguishes between internal and external sounds. • Separate research has identified a gut-based mechanism that links sleep apnea to an increased risk of heart disease. • These findings are significant as they provide deeper insights into brain plasticity and uncover a potential biological pathway for protecting the heart from sleep-related breathing disorders.

• Scientists have identified a new blood marker capable of detecting lung cancer years earlier than traditional imaging scans. • Researchers from the University of Cambridge and DIOSynVax successfully completed the first human clinical trial for a "universal" coronavirus vaccine. • The experimental vaccine, tested on 39 healthy volunteers, proved safe and aims to protect against an entire family of related viruses to prevent future pandemics.

• Geopolitical risk is emerging as a critical factor influencing global financial stability, as detailed in the June 2026 Bulletin. • These risks extend to organizational capacity, specifically threatening the stability of offshore teams and third-party service providers. • Conflict, communication outages, and general disruptions can impair the ability of financial institutions to maintain essential operations.

• A new study highlights that regular exercise, such as brisk walking or cycling, combined with adequate sleep is linked to improved mental health during midlife. • Separate research on mice indicates that diets rich in polyunsaturated fatty acids (PUFAs), specifically omega-3s from fish oil, significantly slowed cancer development. • The fish oil-enriched diets resulted in an approximate 50% reduction in disease burden compared to standard fat diets, contradicting expectations regarding the benefits of oleic acid.

• An experimental drug called daraxonrasib demonstrated a significant survival benefit for patients with metastatic pancreatic cancer in a global Phase 3 clinical trial. • The study involving 500 patients showed that those receiving daraxonrasib had a median overall survival of 13.2 months, nearly double the 6.7 months seen in the standard chemotherapy group. • This breakthrough is critical as it reduced the risk of death by 60% for patients whose disease had already progressed after initial chemotherapy.